Overview
A venture-backed technology company, funded by the likes of Greylock Partners, needed an important board update package built to an institutional standard. The leadership team needed their full attention on strategic preparation and stakeholder alignment ahead of the meeting, and building the materials themselves would have consumed the team's limited resources. Several team members had worked with VERBED before and recommended us, confident we could deliver within their timeframe.
The Mandate
The company was navigating a period of market uncertainty and a refocusing of its executive team and overall strategy. The board package had to communicate that strategy so the board could understand it clearly, engage with it, and act on it, and so the board could place its confidence in the executive team. Materials of real quality are the cornerstone of that confidence. The company trusted us with the board package, so the founder and executives could stay on the high-leverage preparation ahead of the meeting.
Outcome
The leadership team was able to communicate a confident vision for the company's future at a moment when the market offered little certainty. The materials exceeded what the founder, someone with high standards for presentation quality, had thought possible, and the quality and clarity of the final package set a new internal benchmark for the organisation.

A public company with billions in market cap at stake

Investor materials for a multi-billion-dollar consumer VC

A confident board update for an uncertain market

From overlooked to 3x oversubscribed

A first fund worthy of a global name

LP materials that raised $190M, 30% over target

From first raise to strategic exit

The M&A package that created millions in accretive value

From wholesaler to scalable platform

The $1.6B presentation

Partnership conversations at the industry's biggest week

A global rebrand and product launch

A decade as an extension of the executive team

A brand from scratch for a Super Bowl champion

Carrying authority into new clinical ground

AGM preparation while the CEO closed multiple acquisitions







